HM 12525A

Drug Profile

HM 12525A

Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM12525A; JNJ-64565111; LAPS GLP/GCG; LAPS- GLP/Glucagon; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG; Oxyntomodulin immunoglobulin conjugate

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Hanmi Pharmaceutical; Janssen Pharmaceuticals
  • Class Antihyperglycaemics; Drug conjugates; Gastrointestinal hormones; Glucagon-like peptides; Immunoconjugates; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 04 Aug 2017 Janssen plans a phase I trial for Type-2 diabetes mellitus in USA (NCT03235219)
  • 01 Aug 2017 Phase-Ib clinical trials in Type-2 diabetes mellitus (In adults, In the elderly) in USA (SC) (NCT03235219)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top